Last reviewed · How we verify
Sodium Ozagrel
Sodium ozagrel inhibits thromboxane A2 synthetase, reducing platelet aggregation and thrombosis.
Sodium ozagrel inhibits thromboxane A2 synthetase, reducing platelet aggregation and thrombosis. Used for Acute ischemic stroke, Prevention of thrombotic events in cardiovascular disease.
At a glance
| Generic name | Sodium Ozagrel |
|---|---|
| Sponsor | Tanabe Pharma Corporation |
| Drug class | Thromboxane A2 synthetase inhibitor |
| Target | Thromboxane A2 synthetase |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Ozagrel is a thromboxane A2 (TXA2) synthetase inhibitor that blocks the production of thromboxane A2, a potent platelet aggregator and vasoconstrictor. By reducing TXA2 levels, the drug decreases platelet aggregation and prevents thrombotic events. This mechanism makes it useful in preventing ischemic complications in cardiovascular and cerebrovascular conditions.
Approved indications
- Acute ischemic stroke
- Prevention of thrombotic events in cardiovascular disease
Common side effects
- Bleeding
- Gastrointestinal disturbance
- Headache
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sodium Ozagrel CI brief — competitive landscape report
- Sodium Ozagrel updates RSS · CI watch RSS
- Tanabe Pharma Corporation portfolio CI